DENTSPLY SIRONA emerged from its Q1 results this week with a mixed scorecard — a top-line beat offset by a slim EPS miss — and a short base that, despite trimming slightly, remains near its highest level in a year.
Short sellers hold a firm grip on this stock. SI % of free float closed at 9.9% on May 5, down modestly from a mid-April peak above 10.2% but still sharply above the 9.2%–9.5% range that prevailed through March and early April. That April step-up — shorts added roughly a full percentage point of float between early April and mid-month — coincided with a period of increasing uncertainty ahead of earnings. The past week saw a small retreat, with shares outstanding falling around 2.2%, but the base remains structurally elevated. FINRA's most recent official count, settled April 15, put shorts at 20.3 million shares with 7.1 days to cover — confirming this is a meaningfully held short position, not a fringe bet.
The lending market is not adding squeeze pressure. Availability has loosened compared to earlier in April, and the cost to borrow has actually fallen — down 12% over the past week to 0.45%. At that level, the borrow is near free; there is no cost-of-carry pain pushing shorts to cover. Options positioning has pulled back from its most defensive readings: the put/call ratio eased to 0.90 from above 0.96 earlier in the week. That is still above the 20-day average of 0.76, but the z-score of 0.9 suggests this is modest caution rather than outright alarm. Heading into earnings, the market had priced in some risk; the stock's flat-ish reaction — up 1.5% on May 5 after the print — suggests the market found the results tolerable rather than alarming.
The analyst community is divided, and the division has sharpened this week. Mizuho cut its price target to $14 from $16 this morning while staying Neutral — a signal that its analyst sees the restructuring story as slower than previously modelled. Citigroup initiated coverage in mid-April with a Sell and a $10 target, the only outright bear call on the Street. Against those sits a solitary Outperform from Barrington Research at $17 and a Buy from BofA at $17 — the latter upgraded in February. The consensus clusters firmly at Hold, with 12 of 13 rated analysts sitting on the fence. The mean price target is $13.67 — about 20% above the current $11.37 close — which sounds constructive, but with the range spanning $10 to $17 and the most recent move being a target cut, the direction of travel is cautious. On valuation, the stock trades at 7.7x trailing earnings and 7.0x EV/EBITDA, both of which have compressed modestly over the past month, reflecting the market's reluctance to pay up while the turnaround remains unproven.
The bull and bear cases are well-defined at this point. Bulls point to Q1 revenue of $880 million, which beat estimates of $843 million, full-year guidance reiterated at $3.5–3.6 billion in sales and $1.40–$1.50 in adjusted EPS, a restructuring targeting roughly $120 million in annual savings, and the decision to eliminate the dividend to pay down debt. Bears point to the EPS miss ($0.27 vs. $0.28 expected), persistent executive turnover including a CFO departure, margin contraction, and a track record of failed prior turnaround plans. Dentsply also launched a new AI diagnostic tool targeting 3D dental scans — a product initiative that speaks to longer-term positioning but offers no near-term earnings relief.
Institutional ownership adds an interesting wrinkle. Southpoint Capital Advisors entered as a fresh holder with 10 million shares — a 5% stake — as of mid-March. That is the largest new position in the top-15 ownership table and suggests at least one active manager made a deliberate bet on the recovery thesis around the same level as the Chairman's open-market purchase. Greg Lucier, Chairman of the Board, bought 15,000 shares at $12.44 in early March; Director Jim Forbes added 5,000 shares at the same time. Those buys are now underwater, with the stock trading at $11.37.
With Q2 results now pencilled in for June 2, the next data point that matters is whether management's full-year revenue and EPS guidance holds. The Street's attention will be on whether the restructuring savings are flowing through margins and whether the dental market — softness in which has been a consistent headwind — shows any stabilisation.
See the live data behind this article on ORTEX.
Open XRAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
